Remove Eating disorders Remove Genetics and mental health Remove Information
article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Health care professionals should monitor the child’s growth and development and provide necessary interventions to mitigate weight loss.”

article thumbnail

Eyes, Ears, and Emotion: Techniques to Tackle Diagnosing Bipolar Disorder

Psychiatric Times

Emerging research on RNA biomarkers, AI applications, and genetic mutations shows promise for developing new diagnostic tools for bipolar disorder. 2 With the potential benefits of developing lab-based diagnostic tools, there are unfortunately no definitive blood tests for bipolar disorder currently.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ADHD Treatment Options

Psychiatric Times

Related Videos Related Content Advertisement June 17th 2025 ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment David N. Newsletter Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients. Subscribe Now!

article thumbnail

Risk Factors for ADHD

Psychiatric Times

Overview of Attention Deficit/Hyperactivity Disorder EP: 2. Role of Pediatricians in Diagnosing ADHD ADHD risk factors encompass both genetic and environmental components that significantly impact child development. ADHD in Elementary School Age Child: Patient Case 1 EP: 3. ADHD Diagnosis Criteria EP: 4. Risk Factors for ADHD EP: 7.

article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. 1 The company has previously filed the required Chemistry, Manufacturing, and Controls (CMC) information and received FDA feedback.

article thumbnail

Nonstimulant Therapies for ADHD

Psychiatric Times

Both medications carry important safety considerations including potential for increased suicidal ideation, requiring careful monitoring and education about distinguishing medication-related intrusive thoughts from situational mental health concerns. Subscribe Now!

article thumbnail

The Psychiatric Pipeline in Review: Quarter 2, 2025

Psychiatric Times

Together, they will aim to bring innovative mental health treatments to patients in need. Participants include 30 young adults diagnosed with BPD and 20 young adults with no mental health diagnosis, who are observed using EEG and behavioral assessments to gather objective data.